HVTN 092

Status:Completed
Phase:I
Principal Investigator(s):Giuseppe Pantaleo
Objective:To evaluate DNA schedule/NYVAC.
Prevention Option(s):HIV Vaccine
Study Design:
Arms and Assigned Interventions
DescriptionParticipants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) in the same deltoid at Days 0, 14, and 28.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code: NCT01783977
Trial Sponsors: NIAID
Start Date
End Date
April 1, 2013
October 4, 2018
Enrollment:204
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women